Glaucoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with complex, refractory, or high-risk ocular conditions, including but not limited to: Advanced glaucoma refractory to conventional therapy. Acute primary angle-closure glaucoma (in the attack phase). Established malignant glaucoma. Nanophthalmos (with or without secondary glaucoma). Anatomical predisposition (e.g., short axial length, shallow anterior chamber) conferring a high risk of malignant glaucoma. 2. Clinically significant cataract planned for surgical removal. 3. Age between 18 and 75 years. 4. Willingness to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients deemed by the investigator to have systemic diseases (e.g., Sjögren's syndrome) that may increase surgical risk or compromise postoperative outcomes. 2. Patients using systemic or ocular medications (e.g., chlorpromazine, ethambutol, digitalis, chloroquine) that, in the investigator's judgment, may confound study results or pose additional risk to the subject. 3. Patients with traumatic cataract or bilateral congenital cataract. 4. Women who are pregnant, lactating, planning a pregnancy in the near future, or who have other conditions associated with hormonal fluctuations. 5. Participation in another investigational medical device trial within 30 days prior to screening, or in an investigational drug trial within 3 months prior to screening. 6. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure;Visual acuity;Anterior chamber depth; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual quality; | — |
Countries
China
Contacts
Eye Hospital of Wenzhou Medical University